KALA BIO, Inc. (NASDAQ:KALA – Get Free Report) was the target of a significant decrease in short interest in May. As of May 15th, there was short interest totaling 42,592 shares, a decrease of 95.9% from the April 30th total of 1,029,124 shares. Based on an average daily trading volume, of 90,516 shares, the days-to-cover ratio is presently 0.5 days. Approximately 0.2% of the shares of the stock are short sold.
Institutional Inflows and Outflows
Large investors have recently bought and sold shares of the stock. Woodline Partners LP acquired a new position in KALA BIO in the first quarter valued at about $1,483,000. Geode Capital Management LLC lifted its position in KALA BIO by 2.8% in the second quarter. Geode Capital Management LLC now owns 56,367 shares of the company’s stock valued at $268,000 after buying an additional 1,534 shares during the last quarter. Jane Street Group LLC acquired a new stake in shares of KALA BIO during the fourth quarter worth about $80,000. XTX Topco Ltd acquired a new stake in shares of KALA BIO during the second quarter worth about $62,000. Finally, Virtu Financial LLC acquired a new stake in shares of KALA BIO during the fourth quarter worth about $48,000. Institutional investors and hedge funds own 24.61% of the company’s stock.
Wall Street Analysts Forecast Growth
KALA has been the subject of a number of research reports. Wall Street Zen raised shares of KALA BIO from a “sell” rating to a “hold” rating in a report on Sunday. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of KALA BIO in a report on Friday, March 27th. One equities research analyst has rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $1,018.75.
KALA BIO Trading Up 7.4%
NASDAQ KALA traded up $0.16 during trading hours on Wednesday, reaching $2.33. The company had a trading volume of 45,983 shares, compared to its average volume of 80,065. The stock has a 50-day moving average of $7.13 and a 200 day moving average of $21.31. KALA BIO has a 1-year low of $2.10 and a 1-year high of $1,030.00. The stock has a market capitalization of $43.31 million, a P/E ratio of -0.02 and a beta of -2.23.
KALA BIO (NASDAQ:KALA – Get Free Report) last posted its earnings results on Friday, May 15th. The company reported ($0.14) EPS for the quarter, beating analysts’ consensus estimates of ($8.50) by $8.36.
About KALA BIO
KALA Bio (NASDAQ: KALA) is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel therapies for ocular diseases. The company’s proprietary surface charge–based nanoparticle delivery platform is designed to enhance penetration and retention of therapeutic agents on the ocular surface. This technology is the basis for its lead product, Eysuvis (KPI-121 1.0%), an FDA-approved topical corticosteroid for short-term relief of ocular itching associated with allergic conjunctivitis.
Beyond its approved therapy, KALA Bio is advancing a pipeline of investigational drug candidates targeting inflammatory and degenerative eye conditions.
Read More
- Five stocks we like better than KALA BIO
- Abercrombie Rallies as Strong Q1 Earnings Extend Winning Streak
- TeraWulf Bets on Power Infrastructure to Lead AI Build-Out
- Amazon’s Alexa for Shopping Strengthens an Already Strong Bull Case
- Keysight: The AI and Defense Stock Seeing Big Price Target Boosts
Receive News & Ratings for KALA BIO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KALA BIO and related companies with MarketBeat.com's FREE daily email newsletter.
